RxDoctor Payments Data

Kathryn Cappiello, APRN

Family · Wallingford, CTNPI 1619522257

Payments from drug & device makers

$4,536in general payments, 2019–2025

Across 234 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$809
  • E.r. Squibb & Sons, L.L.C.$665
  • Esperion Therapeutics, Inc.$601
  • Amgen$307
  • Novo Nordisk$301
  • Medtronic$295
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$4,48699%
  • Education$331%
  • Entertainment$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,536 in reported general payments places this provider in the 90th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$19,405
Medicare patients
193
Services billed
298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban63$93,928
XareltoRivaroxaban21$35,531
FarxigaDapagliflozin Propanediol19$16,261
Metoprolol Succinate52$923
Atorvastatin Calcium48$612
Hydralazine Hcl24$590
Amlodipine Besylate98$402
ClopidogrelClopidogrel Bisulfate21$396
Metoprolol Tartrate48$286
Ezetimibe15$232
Furosemide29$217
Lisinopril32$159
Doxazosin Mesylate19$145
Hydrochlorothiazide23$145
Spironolactone19$118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$282$93,92863 claims
Johnson & JohnsonXarelto$809$35,53121 claims
AstraZenecaFarxiga$233$16,26119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,596 family providers in Connecticut.

Other family in Wallingford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →